Skip to content

Effect of high-protein peptide-based formula compared with isocaloric isonitrogenous polymeric formula in critically ill surgical patient

The Effect of peptide-based formula compared with isocaloric, isonitrogenous formula by early enteral feeding in critically-ill patients

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20220507003
Enrollment
54
Registered
2022-05-07
Start date
2019-06-22
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critically-ill patients who admitted on Surgical ICU ward and can start tube feeding after 48 hr post-operation. Peptide-based formula tube feeding critically-ill Surgical ICU

Interventions

Sponsors

Thai Otsuka Pharmaceutical Co., Ltd
Lead Sponsor

Eligibility

Sex/Gender
All
Age
15 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1.Willing to participate clinical study with signing consent form 2.Age 15 year or above 3.Admit on Surgical ICU ward 4.Tend to be prescribed tube feeding in ICU at least 5 days and up to 14 days 5.Risk of malnutrition on mild to moderate by BNT assessment 6.BMI 18-40 kg/m2 7.Can be assigned tube feeding within 48 hr after operation 8.Haemodynamic stable. In case of taking norepinephrine, would take not more than 15 microgram/min or 0.3 microgram/kg/min

Exclusion criteria

Exclusion criteria: 1. Experiences aspiration pneumonia 2. Experiences thyroid disease 3. Experiences severe hepatic impairment 4. Diagnosed to ascites 5. Diagnosed to CKD or renal replacement therapy 6. Diagnosed to abdominal hypertension or fluid overload 7. Takes fentanyl more than 2 microgram per kg per hr or morphine more than 0.05 milligram per kg per hr 8. Has parenteral nutrition administration 9. Experiences food allergy such as Whey Protein, Casein , 10 Diagnosed to incurable disease that could not participate the study such as uncontrolled cancer, 11 Experiences chemotherapy or radiotherapy within 6 months ago. (including immunosuppressor taking such as prednisolone 7 days continuously within 4 months before enrolment , 12 Experiences immune disorder such as HIV-positive 13. Diagnosed to burn at severity level 2 or 3 with wound 50% of total body surface area 14. Taking tube feeding less than 70% of total requirement

Design outcomes

Primary

MeasureTime frame
Daily average gastric residual volume every time before feeding IP Gastric Residual Volume measurement,Fibronectin change Day1,3,5,11,14 Fibronectin level

Secondary

MeasureTime frame
Nutrition status Day1,3,5,7,9,11,14 retinol binding protein, prealbumin, albumin,total lymphocyte count Day 1,3,5,7,9,11,14 CBC,nitrogen balance Day 1,3,5,7,9,11,14 UUN,ICU length of stay Everyday during the study assessment,ICU mortality Everyday during the study assessment ,duration of hospitalization Everyday during the study assessment ,GI side effect Everyday during the study assessment ,Rate of infection Everyday during the study assessment

Countries

Thailand

Contacts

Public ContactThipvadee Yamchuenpong

THAI OTSUKA PHARMACEUTICAL CO., LTD

thipvadee@thai-otsuka.co.th0632378178

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026